Varda Space Industries and United Therapeutics have entered a research collaboration to explore whether microgravity can produce improved formulations of medicines for rare pulmonary diseases, extending efforts to move pharmaceutical development and manufacturing into low Earth orbit
The collaboration will study how the near-weightless environment of space affects pharmaceutical crystallization and whether those changes can create formulations with properties that are difficult to achieve under normal conditions on Earth. Varda describes the project as its first space-based drug-formulation collaboration aimed at potentially producing therapies for patients.
Why Microgravity Matters for Drug Development
Gravity affects how pharmaceutical crystals form. In microgravity, convection, buoyancy and sedimentation are substantially reduced, which can change crystal size, structure and uniformity.
According to Varda, those conditions can potentially produce more uniform particles or different crystal structures, characteristics that can influence factors including drug delivery, bioavailability, stability and manufacturing.
The concept is not entirely new. Pharmaceutical crystallization experiments have been conducted in space for decades, including research involving biologic medicines aboard the International Space Station. The commercial challenge has been developing repeatable access to orbit and a system capable of returning pharmaceutical materials to Earth for analysis and further development.
Varda Builds an Orbital Pharmaceutical Platform
Varda is developing autonomous spacecraft that carry pharmaceutical experiments into low Earth orbit, process materials under microgravity and return the resulting samples to Earth.
The company says its earlier missions demonstrated controlled pharmaceutical crystallization in orbit and the ability to return those materials for analysis. Its longer-term objective is to integrate space-based processing into conventional pharmaceutical development rather than treat microgravity experiments primarily as scientific research.
That strategy received additional financial backing this week. Varda announced a $251 million Series D financing round, bringing the total capital raised by the company to $598 million. The funding is intended to help scale its space-based pharmaceutical processing operations.
The United Therapeutics collaboration provides a commercial test of that model: whether pharmaceutical materials processed in orbit can demonstrate characteristics significant enough to eventually translate into improved drug formulations on Earth.
For the pharmaceutical industry, the broader significance is not simply whether medicines can be produced in space, but whether microgravity can become a practical additional variable in drug development — alongside chemistry, temperature, pressure and other conditions already manipulated in laboratories on Earth.
